EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

No replicating evidence for anti‐amyloid‐β autoantibodies in cerebral amyloid angiopathy‐related inflammation

Emma van den Berg iD, Rian Roelofs, Lieke Jäkel, Steven M Greenberg, Andreas Charidimou, Ellis S van Etten iD, Delphine Boche, Catharina J M Klijn iD, Floris H B M Schreuder iD, H Bea Kuiperij iD, Marcel M Verbeek iD

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Emma van den Berg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Autoantibodies, Amyloid beta-Peptides. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Dutch Brain Foundation, Dutch Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Elevated levels of anti‐amyloid‐β (anti‐Aβ) autoantibodies in cerebrospinal fluid (CSF) have been proposed as a diagnostic biomarker for cerebral amyloid angiopathy‐related inflammation (CAA‐RI). We aimed to independently validate the immunoassay for quantifying these antibodies and evaluate its diagnostic value for CAA‐RI.

Methods

We replicated the immunoassay to detect CSF anti‐Aβ autoantibodies using CSF from CAA‐RI patients and non‐CAA controls with unrelated disorders and further characterized its performance. Moreover, we conducted a literature review of CAA‐RI case reports to investigate neuropathological and CSF evidence of the nature of the inflammatory reaction in CAA‐RI.

Results

The assay demonstrated a high background signal in CSF, which increased and corresponded with higher total immunoglobulin G (IgG) concentration in CSF ( r sp = 0.51, p = 0.02). Assay levels were not elevated in CAA‐RI patients ( n = 6) compared to non‐CAA controls ( n = 20; p = 0.64). Literature review indicated only occasional presence of B‐lymphocytes and plasma cells (i.e., antibody‐producing cells), alongside the abundant presence of activated microglial cells, T‐cells, and other monocyte lineage cells. CSF analysis did not convincingly indicate intrathecal IgG production.

Interpretation

We were unable to reproduce the reported elevation of anti‐Aβ autoantibody concentration in CSF of CAA‐RI patients. Our findings instead support nonspecific detection of IgG levels in CSF by the assay. Reviewed CAA‐RI case reports suggested a widespread cerebral inflammatory reaction. In conclusion, our findings do not support anti‐Aβ autoantibodies as a diagnostic biomarker for CAA‐RI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Amyloid AngiopathyAutoantibodiesAmyloid beta-PeptidesHumansAgedFemaleMaleMiddle AgedBiomarkersInflammationAged, 80 and overNeuroinflammatory DiseasesImmunoglobulin G

Substanzen

AutoantibodiesAmyloid beta-PeptidesBiomarkersImmunoglobulin G

Autor:innen und Institutionen

  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Neurology, Boston University Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.

ORCID-Profile: Emma van den Berg, Ellis S van Etten, Catharina J M Klijn, Floris H B M Schreuder, H Bea Kuiperij, Marcel M Verbeek

Förderung

  • NINDS NIH HHS
  • Dutch Brain Foundation
  • Dutch Heart Foundation
  • Stryker
  • Top Sector Life Sciences & Health
  • The Galen and Hilary Weston Foundation
  • Alzheimer Nederland
  • Cerenovus

Zitieren

APA

van den Berg, E., Roelofs, R., Jäkel, L., Greenberg, S. M., Charidimou, A., van Etten, E. S., Boche, D., Klijn, C. J. M., Schreuder, F. H. B. M., Kuiperij, H. B., & Verbeek, M. M. (2024). No replicating evidence for anti‐amyloid‐β autoantibodies in cerebral amyloid angiopathy‐related inflammation. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52169

Vancouver

van den Berg E, Roelofs R, Jäkel L, Greenberg SM, Charidimou A, van Etten ES, et al. No replicating evidence for anti‐amyloid‐β autoantibodies in cerebral amyloid angiopathy‐related inflammation. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52169

BibTeX
@article{vandenBerg2024,
  author = {van den Berg, Emma and Roelofs, Rian and Jäkel, Lieke and Greenberg, Steven M and Charidimou, Andreas and van Etten, Ellis S and Boche, Delphine and Klijn, Catharina J M and Schreuder, Floris H B M and Kuiperij, H Bea and Verbeek, Marcel M},
  title = {No replicating evidence for anti‐amyloid‐β autoantibodies in cerebral amyloid angiopathy‐related inflammation},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52169}
}
Kostenlos starten →